IMR Press / JOMH / Special Issues / 1417754240028164096

Diagnosis and treatment of clinically localized prostate cancer: a urological conundrum

Submission deadline: 31 March 2022
Special Issue Editor
  • Angelo Naselli, MD
    Department of Urology , Ospedale Classificato San Giuseppe, gruppo Multimedica, Milano (MI), Italy
    Interests: Bladder; Prostate; Kidney cancer mainly
Special Issue Information

Prostate cancer (PC) is the most common urological malignancy. Estimated new cases and mortality are respectively 13.1% of new cancers and 5.6% of all cancer deaths in 2021 according to the SEER program database The prevalence of incidental PC is high as it is found in about 60% of man aged 80 or more years. Even patients of 60 or more years with a baseline PSA of 4 or less have a 15% risk of being detect with PC by biopsy. Therefore, the chance to be diagnosed with PC is sensibly high at any age after testing for PSA. The benefit of an early diagnosis is not yet fully understood. PLCO and ERSCP trials did not give a final answer to the dilemma. After a diagnosis of clinically localized PC, the main issue is to identify which patients will benefit from treatment and which treatment fits more according to patient and disease characteristics. The SPCG-4, PIVOT and ProtecT trials did not disclose a clear advantage of treatment versus observation and of any treatment versus another. Active surveillance and multiparametric MR of the prostate are relatively new modalities which may help identify patients at risk. Meanwhile, technological improvements of treatments and related costs skyrocketed making PC one of the more controversial disease of the modern history.

The aim of the special issue is to give an insight in the topic. Beside well-known and established studies, reporting the own clinical experience or, alternatively, enlighten with a different interpretation of available data may really help to improve the treatment of our patients.

Keywords
Prostatic neoplasms
Early diagnosis
Mortality
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top